The alternative mechanism for PD-L1 upregulation on tumors that has emerged from both clinical and pre-clinical studies reflects their adaptation to endogenous tumor-specific immune responses, known as adaptive immune resistance [46, 47]. The gene discussed is CD274; the disease is neoplasm.